Abstract
Nowadays, the main method for assessing the efficiency of pharmacologic therapies are the randomized controlled trials (RCTs), which are regarded as an objective measure of the biologic response of the patients to a given treatment. However, beside quantifying therapeutic responses, there are many other subjective factors (emotional factors such as depression or anxiety, ability to perform daily activities at the workplace or at home, changes in eating/sleeping, social, familiar, and sexual habits), which are difficult to assess using quantitative methods. Both dyspepsia and quality of life (QoL) are ill-defined terms [1, 2]. Physicians traditionally prefer to use objective methods to diagnose and monitor treatment responses. However, many gastrointestinal diseases have a high symptom burden and enormous health-care costs but little objective evidence of the disease; this is especially true for the large group of functional disorders to which dyspepsia belongs [3, 4].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have